Clinical trial
Medication, Weight Gain and GI Hormones
NCT00384332 · Vanderbilt University, Other · Completed
Key facts
| NCT number | NCT00384332 |
|---|---|
| Title | Medication, Weight Gain and GI Hormones |
| Official title | Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones |
| Lead sponsor | Vanderbilt University, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Depression |
| Intervention type | Drug |
| Interventions | orally-disintegrating olanzapine, regular olanzapine |
| Enrollment | 20 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | Jul 31, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: